Liver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+CD11b+ myeloid cells

Journal of Leukocyte Biology

Volumn 96, Issue 5, 2014, Pages 883-894

  Thorn, Mitchell ^a   Point, Gary R ^a   Burga, Rachel A ^a   Nguyen, Cang T ^a   Joseph Espat, N ^a,b   Katz, Steven C ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; Immunosuppression; Liver; STAT3

Indexed keywords

B LYMPHOCYTE RECEPTOR; B7 ANTIGEN; CD11B ANTIGEN; CD19 ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; CD86 ANTIGEN; CELL SURFACE RECEPTOR; GRANULOCYTE RECEPTOR 1, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL CONTACT; CELL COUNT; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; LIVER CELL; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ADOPTIVE TRANSFER; ANIMAL; B LYMPHOCYTE; DISEASE MODEL; IMMUNOLOGY; LIVER NEOPLASMS; LUMINESCENCE; LYMPHOCYTE ACTIVATION; METABOLISM; METASTASIS; MOLECULAR IMAGING; PROCEDURES; SECONDARY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTE SUBSETS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOWN-REGULATION; LIVER NEOPLASMS; LUMINESCENT MEASUREMENTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MOLECULAR IMAGING; MYELOID CELLS; NEOPLASM METASTASIS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN;

EID: 84908300004     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.3A0114-012RR     Document Type: Article

References (53)

1. Burghardt, S., Erhardt, A., Claass, B., Huber, S., Adler, G., Jacobs, T., Chalaris, A., Schmidt-Arras, D., Rose-John, S., Karimi, K., Tiegs, G. (2013) Hepatocytes contribute to immune regulation in the liver by activation of the notch signaling pathway in T cells. J. Immunol. 191, 5574–5582.
2. Connolly, M. K., Bedrosian, A. S., Malhotra, A., Henning, J. R., Ibrahim, J., Vera, V., Cieza-Rubio, N. E., Hassan, B. U., Pachter, H. L., Cohen, S., Frey, A. B., Miller, G. (2010) In hepatic fibrosis, liver sinusoidal endothelial cells acquire enhanced immunogenicity. J. Immunol. 185, 2200–2208.
3. Katz, S. C., Pillarisetty, V. G., Bleier, J. I., Shah, A. B., DeMatteo, R. P. (2004) Liver sinusoidal endothelial cells are insufficient to activate T cells. J. Immunol. 173, 230–235.
4. Valzasina, B., Piconese, S., Guiducci, C., Colombo, M. P. (2006) Tumorinduced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 66, 4488–4495.
5. Huang, B., Pan, P. Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., Chen, S. H. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123–1131.
6. Connolly, M. K., Mallen-St Clair, J., Bedrosian, A. S., Malhotra, A., Vera, V., Ibrahim, J., Henning, J., Pachter, H. L., Bar-Sagi, D., Frey, A. B., Miller, G. (2010) Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra- abdominal tumor. J. Leukoc. Biol. 87, 713–725.
7. De Palma, M. (2012) Partners in crime: VEGF and IL-4 conscript tumour- promoting macrophages. J. Pathol. 227, 4–7.
8. Rosenberg, S. A., Yang, J. C., Restifo, N. P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915.
9. De Visser, K. E., Schumacher, T. N., Kruisbeek, A. M. (2003) CD8+ T cell tolerance and cancer immunotherapy. J. Immunother. 26, 1–11.
10. Siegel, C. T., Schreiber, K., Meredith, S. C., Beck-Engeser, G. B., Lancki, D. W., Lazarski, C. A., Fu, Y. X., Rowley, D. A., Schreiber, H. (2000) Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J. Exp. Med. 191, 1945–1956.
11. Novobrantseva, T. I., Majeau, G. R., Amatucci, A., Kogan, S., Brenner, I., Casola, S., Shlomchik, M. J., Koteliansky, V., Hochman, P. S., Ibraghimov, A. (2005) Attenuated liver fibrosis in the absence of B cells. J. Clin. Invest. 115, 3072–3082.
12. Moore, J. W., Beattie, L., Dalton, J. E., Owens, B. M., Maroof, A., Coles, M. C., Kaye, P. M. (2012) B cell: T cell interactions occur within hepatic granulomas during experimental visceral leishmaniasis. PLoS One 7, e34143.
13. Shah, S., Divekar, A. A., Hilchey, S. P., Cho, H. M., Newman, C. L., Shin, S. U., Nechustan, H., Challita-Eid, P. M., Segal, B. M., Yi, K. H., Rosenblatt, J. D. (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117, 574–586.
14. Barbera-Guillem, E., Nelson, M. B., Barr, B., Nyhus, J. K., May, Jr., K. F., Feng, L., Sampsel, J. W. (2000) B lymphocyte pathology in human colorectal cancer experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol. Immunother. 48, 541–549.
15. Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X., Blankenstein, T. (1998) B Cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4, 627–630.
16. Schultz, K. R., Klarnet, J. P., Gieni, R. S., HayGlass, K. T., Greenberg, P. D. (1990) The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249, 921–923.
17. DiLillo, D. J., Yanaba, K., Tedder, T. F. (2010) B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184, 4006–4016.
18. Rodriguez-Pinto, D. (2005) B Cells as antigen presenting cells. Cell. Immunol. 238, 67–75.
19. Watt, V., Ronchese, F., Ritchie, D. (2007) Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J. Immunother. 30, 323–332.
20. Schmidt, M., Bohm, D., von Torne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H. A., Hengstler, J. G., Kolbl, H., Gehrmann, M. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405–5413.
21. Milne, K., Kobel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., Nelson, B. H. (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4, e6412.
22. Katz, S. C., Pillarisetty, V. G., Bleier, J. I., Kingham, T. P., Chaudhry, U. I., Shah, A. B., DeMatteo, R. P. (2005) Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors. Hepatology 42, 293–300.
23. Ma, C., Kapanadze, T., Gamrekelashvili, J., Manns, M. P., Korangy, F., Greten, T. F. (2012) Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 92, 1199–1206.
24. Danna, E. A., Sinha, P., Gilbert, M., Clements, V. K., Pulaski, B. A., Ostrand- Rosenberg, S. (2004) Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 64, 2205–2211.
25. Kusmartsev, S., Nefedova, Y., Yoder, D., Gabrilovich, D. I. (2004) Antigen- specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989–999.
26. Green, K. A., Cook, W. J., Green, W. R. (2013) Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. J. Virol. 87, 2058–2071.
27. Emtage, P. C., Lo, A. S., Gomes, E. M., Liu, D. L., Gonzalo-Daganzo, R. M., Junghans, R. P. (2008) Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin. Cancer Res. 14, 8112–8122.
28. Jenkins, M. K., Taylor, P. S., Norton, S. D., Urdahl, K. B. (1991) CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 147, 2461–2466.
29. Kosco-Vilbois, M. H., Gray, D., Scheidegger, D., Julius, M. (1993) Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/BB1 and upregulation of major histocompatibility complex class II molecules. J. Exp. Med. 178, 2055–2066.
30. Boyd, A. W., Wawryk, S. O., Burns, G. F., Fecondo, J. V. (1988) Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact- mediated immune mechanisms. Proc. Natl. Acad. Sci. USA 85, 3095–3099.
31. McFarland, B. C., Gray, G. K., Nozell, S. E., Hong, S. W., Benveniste, E. N. (2013) Activation of the NF-kappaB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol. Cancer Res. 11, 494–505.
32. Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., Gabrilovich, D. I. (2009) Mechanism regulating reactive oxygen species in tumorinduced myeloid-derived suppressor cells. J. Immunol. 182, 5693–5701.
33. Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., Gabrilovich, D. I. (2005) Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65, 9525–9535.
34. Houghton, A. N., Uchi, H., Wolchok, J. D. (2005) The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 7, 403–405.
35. Schreiber, H., Wu, T. H., Nachman, J., Rowley, D. A. (2000) Immunological enhancement of primary tumor development and its prevention. Semin. Cancer Biol. 10, 351–357.
36. Brodt, P., Gordon, J. (1978) Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J. Immunol. 121, 359–362.
37. Zhang, H., Stolz, D. B., Chalasani, G., Thomson, A. W. (2013) Hepatic B cells are readily activated by Toll-like receptor-4 ligation and secrete less interleukin-10 than lymphoid tissue B cells. Clin. Exp. Immunol. 173, 473–479.
38. DiLillo, D. J., Matsushita, T., Tedder, T. F. (2010) B10 Cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer Ann. N. Y. Acad. Sci. 1183, 38–57.
39. Damle, N. K., Klussman, K., Linsley, P. S., Aruffo, A., Ledbetter, J. A. (1992) Differential regulatory effects of intercellular adhesion molecule- 1 on costimulation by the CD28 counter-receptor B 7. J. Immunol. 149, 2541–2548.
40. Jomantaite, I., Dikopoulos, N., Kroger, A., Leithauser, F., Hauser, H., Schirmbeck, R., Reimann, J. (2004) Hepatic dendritic cell subsets in the mouse. Eur. J. Immunol. 34, 355–365.
41. Constant, S., Schweitzer, N., West, J., Ranney, P., Bottomly, K. (1995) B Lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J. Immunol. 155, 3734–3741.
42. O’Neill, S. K., Cao, Y., Hamel, K. M., Doodes, P. D., Hutas, G., Finnegan, A. (2007) Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179, 5109–5116.
43. Lim, T. S., Goh, J. K., Mortellaro, A., Lim, C. T., Hammerling, G. J., Ricciardi- Castagnoli, P. (2012) CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS One 7, e45185.
44. Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., Ren, X. (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190, 3783–3797.
45. Toh, B., Wang, X., Keeble, J., Sim, W. J., Khoo, K., Wong, W. C., Kato, M., Prevost-Blondel, A., Thiery, J. P., Abastado, J. P. (2011) Mesenchymal transition and dissemination of cancer cells is driven by myeloidderived suppressor cells infiltrating the primary tumor. PLoS Biol. 9, e1001162.
46. Serafini, P., Mgebroff, S., Noonan, K., Borrello, I. (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439–5449.
47. Chen, S., Akbar, S. M., Abe, M., Hiasa, Y., Onji, M. (2011) Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin. Exp. Immunol. 166, 134–142.
48. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., Carbone, D. P. (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3, 483–490.
49. Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., Clements, V. K. (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 22, 275–281.
50. Malmberg, K. J. (2004) Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol. Immunother. 53, 879–892.
51. Huang, X., Moore, D. J., Mohiuddin, M., Lian, M. M., Kim, J. I., Sonawane, S., Wang, J., Gu, Y., Yeh, H., Markmann, J. F., Deng, S. (2008) Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance. Transplantation 85, 675–680.
52. Maltzman, J. S., Carmen, J. A., Monroe, J. G. (1996) Transcriptional regulation of the ICAM-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR 1. J. Exp. Med. 183, 1747–1759.
53. Cerny, A., Kimoto, M., Hugin, A. W., Merino, R., Izui, S. (1989) Anti- IgM treatment of C57BL/6-1pr/1pr mice: depletion of B cells reduces 1pr gene-induced lymphoproliferation and mononuclear cell vasculitis. Clin. Exp. Immunol. 77, 124–129.